Country: Israel
Language: English
Source: Ministry of Health
MELATONIN
NEURIM PHARMACEUTICALS (1991) LTD, ISRAEL
N05CH01
TABLETS PROLONGED RELEASE
MELATONIN 5 MG
PER OS
Required
NEURIM PHARMACEUTICALS LIMITED
MELATONIN
Slenyto is indicated for the treatment of insomnia in children and adolescents aged 2-18 with Autism Spectrum Disorder (ASD) and/or Smith-Magenis syndrome, where sleep hygiene measures have been insufficient.
2020-11-15
[לוגו מדינת ישראל] [http://www.gov.il/] [http://www.gov.il/] [לוגו משרד הבריאות] [לוגו משרד הבריאות] [*5400] [http://www.health.gov.il/PniyotHazibur/Pages/CallCenter.aspx] [http://www.health.gov.il/PniyotHazibur/Pages/CallCenter.aspx] הציבור הרחב עסקים ומוסדות עובדים בבריאות חפש מידע תפריט * [סגירה] סגור * דף הבית [http://www.health.gov.il/] * אודות * אודות המשרד [http://www.health.gov.il/About/Pages/about_us.aspx] * תוכנית עבודה [http://www.health.gov.il/About/Pages/Agenda.aspx] * תקציב המשרד [http://www.health.gov.il/About/Pages/budget.aspx] * תרשים מבנה ארגוני [http://www.health.gov.il/About/Pages/OrganizationalStructureDiagram.aspx] * בעלי תפקידים [http://www.health.gov.il/About/Phonebook/Pages/PhoneBook.aspx] * יחידות המשרד [http://www.health.gov.il/UnitsOffice/Pages/UnitsList.aspx] * לשכות הבריאות [http://www.health.gov.il/About/Phonebook/Pages/PhoneBook.aspx?tab=3] * אמנת שירות [http://www.health.gov.il/About/sla/Pages/default.aspx] * אותות ופרסים [http://www.health.gov.il/About/Awards/Pages/mifal.aspx] * פרוייקטים תשתיתיים [http://www.health.gov.il/About/projects/shared_medical_info/Pages/default.aspx] * דרושים [http://www.health.gov.il/About/Careers/Pages/default.aspx] * מנכ"לי משרד הבריאות לדורותיהם [http://www.health.gov.il/About/Pages/GeneralManegerHistory.aspx] * יחידות המשרד * יחידות המשרד [http://www.health.gov.il/UnitsOffice/Pages/UnitsList.aspx] * לשכות הבריאות [http://www.health.gov.il/UnitsOffice/LB/Pages/default.aspx] * וועדות ומועצות [http://www.health.gov.il/Services/Committee/Pages/CommitteeList.aspx] * נושאים * בריאות הנפש [http://www.health.gov.il/Subjects/mental_health/Pages/default.aspx] * בריאות הסביבה [http://www.health.gov.il/Subjects/Environmental_Health/ Read the complete document
1 SUMMARY OF PRODUCT CHARACTERISTICS 1. NAME OF THE MEDICINAL PRODUCT Slenyto 1 mg prolonged-release tablets Slenyto 5 mg prolonged-release tablets 2. QUALITATIVE AND QUANTITATIVE COMPOSITION Slenyto 1 mg prolonged-release tablets Each prolonged-release tablet contains 1 mg melatonin. Excipient with known effect Each prolonged-release tablet contains lactose monohydrate equivalent to 8.32 mg lactose. Slenyto 5 mg prolonged-release tablets Each prolonged-release tablet contains 5 mg melatonin. Excipient with known effect Each prolonged-release tablet contains lactose monohydrate equivalent to 8.86 mg lactose. For the full list of excipients, see section 6.1. 3. PHARMACEUTICAL FORM Prolonged- release tablet. Slenyto 1 mg prolonged-release tablets Pink, film coated, round, biconvex, 3 mm diameter tablets with no imprint. Slenyto 5 mg prolonged-release tablets Yellow, film coated, round, biconvex, 3 mm diameter tablets with no imprint. 4. CLINICAL PARTICULARS 4.1 Therapeutic indications Slenyto is indicated for the treatment of insomnia in children and adolescents aged 2-18 with Autism Spectrum Disorder (ASD) and / or Smith-Magenis syndrome, where sleep hygiene measures have been insufficient. 4.2 Posology and method of administration Posology 2 The recommended starting dose is 2 mg of Slenyto. If an inadequate response has been observed, the dose should be increased to 5 mg, with a maximal dose of 10 mg. Slenyto should be taken once daily, 0.5-1 hour before bedtime and with or after food. Data are available for up to 2 years’ treatment. The patient should be monitored at regular intervals (at least every 6 months) to check that Slenyto is still the most appropriate treatment. After at least 3 months of treatment, the physician should evaluate the treatment effect and consider stopping treatment if no clinically relevant treatment effect is seen. If a lower treatment effect is seen after titration to a higher dose, the prescriber should first consider a down-titration to a lower dose before deciding on a complete d Read the complete document